Medicines Formulary

Reports

Drug name	NICE TAs	Comments
Infliximab	TA134 - Infliximab for the treatment of adults with psoriasis
Inotuzumab ozogamicin (Besponsa®)	TA541 - Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Insulin glargine (lantus®)	TA53 - Guidance on the use of long-acting insulin analogues for the treatment of diabetes - insulin glargene	Extremely high relative cost. Prescribe by brand name.
Interferon Alfa-2B pen	TA75 - Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C TA200 - Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Interferon beta	TA200 - Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C TA527 - Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon gamma	TA32 - Beta interferon and glatiramer acetate for the treatment of multiple sclerosis	For hospital use only
Ipilumumab injection	TA268 - Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma TA319 - Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Irinotecan injection	TA307 - Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy	For hospital use only
Isatuximab	TA658 - Isatuximab with pomalidomide and dexamethasone for treating relapsed and refractory multiple myeloma
Ivabradine tablets	TA267 - Ivabradine for treating chronic heart failure	Consultant to initiate and stabilise patient before GP takes over prescribing

First page
Previous page
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
Next page
Last page

Drug status key

Formulary drugs are allocated a traffic light status. This provides guidance on where clinical and prescribing responsibilities lie in regard to the initiation and maintenance of prescribing.

Grey

Positive NICE TA and/or awaiting local clarification on place in therapy. Please contact your medicines optimisation team for more information.

Red

Initiation and maintenance of prescribing by specialists only.

Amber

Initiation and maintenance of prescribing by specialists and transfer to primary care prescribing when appropriate, or in primary care following a specialists recommendation. Prior to initiation some medicines may require committee agreement or a framework to support safe transfer and maintenance.

Green

Initiation and maintenance of prescribing by specialists, GPs and other qualified clinicians.

Blue

Under review at University Hospitals Birmingham NHS Foundation Trust.